topotecan
information and resources from the National Cancer Institute
NCI Thesaurus | topotecan
A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for topotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.NCI Thesaurus | topotecan
A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for topotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.
Hycamtin
Treatment of patients with metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy.
GlaxoSmithKline May 28 1996
Hycamtin
Treatment of small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy
GlaxoSmithKline Nov 30 1998
|
|
|
|
news articles
First trial to combine a biologic agent with a conventional ... Mar 28, 2006
News-Medical.net, ...released at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers found the addition of thalidomide to topotecan for the ...
Hana Biosciences to License Three Targeted Cancer Drug Candidates ... Mar 17, 2006
Genetic Engineering News, 2006. -- Sphingosomal vinorelbine targeted to start clinical trials in 2006, and sphingosomal topotecan in 2007. -- Proprietary ...
INEX Releases 2005 Operating Results Mar 30, 2006
CNW Telbec (Communiqués de presse), ...(4) The GSK revenue was earned pursuant to an agreement to develop GSK's anticancer drug, topotecan hydrochloride, with the Company's proprietary sphingosomal ...
International Approvals: Rotarix, Hycamtin, Pulmicort HFA Mar 6, 2006
Medscape (subscription) ...has approved a live attenuated rotavirus vaccine for the prevention of rotavirus gastroenteritis in infants, and a new indication for topotecan HCl intravenous ...
Hana will license three cancer drugs for $11.5M Mar 17, 2006
San Francisco Business Times, ...development and sales rights for the chemotherapy drug candidates Marquibo (sphingosomal vincristine), sphingosomal vinorelbine and sphingosomal topotecan. ...
Hana Biosciences to license cancer drugs Mar 17, 2006
BusinessWeek ...for global development and commercialization rights to chemotherapy drugs sphingosomal vincristine, sphingosomal vinorelbine, and sphingosomal topotecan. ...
Inex Signs LoI To License 3 Cancer Products To Hana Biosciences ... Mar 17, 2006
Trading Markets, Pharmaceuticals Corp. (IEX.TO). The three candidates are namely Marqibo, sphingosomal vinorelbine, and sphingosomal topotecan. Upon closing ...
Thalidomide shows promise for ovarian cancer treatment Mar 24, 2006
Minnesota Public Radio, His randomized trial included trial 37 women who received a chemotherapy drug called topotecan. Twenty-eight others took topotecan and thalidomide.
Inex Pharmaceuticals Licenses Three Targeted Chemotherapy Products ... Mar 17, 2006
Canada NewsWire (press release), ...worldwide license to develop and commercialize Marqibo(TM) (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan ...
Hana Paying Up To $42M For Inex’s Cancer Drugs Mar 17, 2006
BioWorld Online (subscription), The other two drugs in the Inex licensing deal, sphingosomal vinorelbine and sphingosomal topotecan, will enter the clinic this year and next, respectively. ...
Insert Therapeutics receives go-ahead for anticancer trials Mar 15, 2006
Pharmaceutical Business Review According to the company, analogues of camptothecin, such as irinotecan and topotecan, realize nearly $1 billion in worldwide sales annually, despite the ...
Insert Therapeutics Receives FDA Approval for Nanotechnology-Based ... Mar 14, 2006
AZoNano.com, Analogues of camptothecin, such as irinotecan and topotecan, realize nearly $1 billion in worldwide sales annually, despite the numerous unwanted side effects ...
Arrowhead Research Subsidiary, Insert Therapeutics, Receives FDA ... Mar 14, 2006
Finanzen.net, Analogues of camptothecin, such as irinotecan and topotecan,realize nearly $1 billion in worldwide sales annually, despite thenumerous unwanted side effects of ...
Hycamtin® receives positive opinion in Europe for treatment of ... Nov 28, 2005
Medical News Today (press release), GlaxoSmithKline (GSK) announced that HYCAMTIN® (topotecan powder for concentration for solution for infusion) received positive opinion from the European ...
INEX Appoints President & CEO and Updates Reorganization Timetable Dec 6, 2005
PR Newswire (press release), ...partnering from its late-stage Targeted Chemotherapy platform including Marqibo(TM), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan). ...
GlaxoSmithKline announces Hycamtin® receives positive opinion in ... Nov 27, 2005
Chemie.de (press release), 11/28/2005 - GlaxoSmithKline (GSK) announced that HYCAMTIN® (topotecan powder for concentration for solution for infusion) received positive opinion from the ...
Combination chemotherapies slow small cell lung cancer and cancer ... Nov 30, 2005
PharmaLive.com (press release), SCRI medical director Dr. F. Anthony Greco led the study comparing the combinations of paclitaxel paired with either topotecan or carboplatin and etoposide for ...
|
|
